ArticleActas espanolas de psiquiatria2026
Effects of Lactate on Improving Cognitive Function and Survival Rate in a Mouse Model of Post-Sepsis Cognitive Impairment.
Article in Actas espanolas de psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-sepsis cognitive impairment (PSCI) represents a prevalent complication observed in survivors of sepsis, manifesting as neurocognitive deficits, including memory impairment and attentional deficits. The precise mechanisms contributing to PSCI are inadequately understood, and there is a notable absence of effective clinical interventions. Lactate, previously considered as a metabolic byproduct, has recently been recognized as a potential energy source and signaling molecule involved in various physiological and pathological processes that are intricately linked to clinical outcomes of sepsis. This study aimed to explore the neuroprotective effects of lactate on PSCI and to elucidate the underlying mechanisms.
methodsSixty male C57BL/6 mice were randomly assigned to three groups: control, sepsis-induced cognitive impairment, and lactate treatment groups. Sepsisassociated cognitive impairment was induced by cecal ligation and puncture. Lactate was administered via daily intraperitoneal injection (1 mol/L, 10 µL/g) for 10 consecutive days beginning 24 hours after surgery, while control groups received saline. Survival and body weight were monitored for 20 days. Cognitive performance was evaluated between days 10 and 15 using established behavioral paradigms. Brain tissue was subsequently collected for histological and molecular analyses.
resultsLactate administration significantly improved survival rates, promoted body weight gain, and enhanced cognitive performance. Additionally, lactate inhibited the activation of the high mobility group box 1 (HMGB1)/receptor for advanced glycation end products (RAGE) axis, reduced neuronal apoptosis and damage, suppressed glial cell activation, reduced Ca
conclusionsLactate emerges as a promising neuroprotective agent against PSCI potentially influencing cerebral energy metabolism, alleviating oxidative stress, and inhibiting neuroinflammation and neuronal damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.